Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

131 studies for “GSK”

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughCompleted
NCT05599191Phase 3Updated Jul 14, 2026
Sponsor: Bellus Health Inc. - a GSK company
Cough · Refractory Chronic Cough
United States, Argentina, Belgium, Canada, Colombia +10 more
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughActive Not Recruiting
NCT05600777Phase 3Updated Jul 14, 2026
Sponsor: Bellus Health Inc. - a GSK company
Cough · Refractory Chronic Cough
United States, Australia, Canada, China, Czechia +8 more
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsActive Not Recruiting
NCT05489237Phase 1Updated Jul 2, 2026
Sponsor: IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Gastrointestinal Neoplasms · Gastrointestinal Stromal Tumor (GIST) · Digestive System Disease · Gastrointestinal Diseases
United States, Belgium, China, France, Germany +6 more
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100Recruiting
NCT06065462Phase 1, Phase 2Updated Jun 23, 2026
Sponsor: M.D. Anderson Cancer Center
Ovarian Clear Cell Carcinoma
United States
TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiationActive Not Recruiting
NCT03833479Phase 2Updated Jun 17, 2026
Sponsor: Grupo Español de Investigación en Cáncer de Ovario
Cervical Cancer · Advanced Cancer
Spain, Turkey (Türkiye)
Pediatric Lupus Trial of Belimumab Plus Background Standard TherapyCompleted
NCT01649765Phase 2Updated Apr 20, 2026
Sponsor: GlaxoSmithKline
Systemic Lupus Erythematosus
United States, Argentina, Canada, Japan, Mexico +5 more
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of AgeCompleted
NCT06222892Phase 1Updated Jan 7, 2026
Sponsor: Bellus Health Inc. - a GSK company
Cough
United States
Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference FormulationCompleted
NCT05570539Phase 1Updated May 18, 2025
Sponsor: Bellus Health Inc. - a GSK company
Cough · Healthy
United Kingdom
Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and CamlipixantCompleted
NCT05959447Phase 1Updated Mar 26, 2025
Sponsor: Bellus Health Inc. - a GSK company
Cough · Healthy
Canada
A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy ParticipantsCompleted
NCT06497517Phase 1Updated Feb 7, 2025
Sponsor: Bellus Health Inc. - a GSK company
Cough
United States
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of CamlipixantCompleted
NCT05899829Phase 1Updated Dec 4, 2024
Sponsor: Bellus Health Inc. - a GSK company
Cough · Healthy
Canada
Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian SubjectsCompleted
NCT06179537Phase 1Updated Dec 22, 2023
Sponsor: Bellus Health Inc. - a GSK company
Healthy
United Kingdom
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)Completed
NCT04173494Phase 3Updated Nov 1, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis
United States, Australia, Austria, Belgium, Bulgaria +17 more
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)Completed
NCT02226965Phase 2Updated Jun 29, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Lymphoma, Diffuse Large B-Cell
United States, Puerto Rico
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)Terminated
NCT02378038Phase 2Updated Jun 29, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Richter's Transformation
United States
Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaTerminated
NCT02101021Phase 3Updated Jun 29, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Metastatic Pancreatic Ductal Adenocarcinoma
United States
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer SubjectsCompleted
NCT02797977Phase 1, Phase 2Updated Jun 22, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Advanced Solid Tumors
Spain, United Kingdom
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaCompleted
NCT01733238Phase 2Updated Jun 22, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Lymphoma, Non-Hodgkin's
United States
A Phase 1/2 Trial of SRA737 in Subjects With Advanced CancerCompleted
NCT02797964Phase 1, Phase 2Updated Jun 18, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
United Kingdom
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaCompleted
NCT02124746Phase 2Updated Jun 18, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis · Polycythemia Vera
United States, Australia, Canada, France, Germany
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Completed
NCT02515630Phase 2Updated Jun 18, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Primary Myelofibrosis (PMF) · Post-polycythemia Vera (Post-PV) Myelofibrosis · Postessential Thrombocythemia (Post-ET) Myelofibrosis
United States, Canada
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFCompleted
NCT02101268Phase 3Updated May 23, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Primary Myelofibrosis (PMF) · Post-polycythemia Vera (Post-PV) · Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
United States, Canada, France, Germany, Israel +3 more
Momelotinib Versus Ruxolitinib in Subjects With MyelofibrosisCompleted
NCT01969838Phase 3Updated May 12, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
United States, Australia, Austria, Belgium, Bulgaria +17 more
A Study of PNT2258 in Patients With Advanced Solid TumorsCompleted
NCT01191775Phase 1Updated Apr 19, 2023
Sponsor: Sierra Oncology LLC - a GSK company
Cancer · Lymphoma · Prostate Cancer · Melanoma
United States
A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic DermatitisCompleted
NCT04693195Phase 2Updated Oct 17, 2022
Sponsor: Bellus Health Inc. - a GSK company
Chronic Pruritus · Atopic Dermatitis
United States, Canada

131 studies found